Abstract
Benign prostatic hyperplasia (BPH) or benign prostatic syndrome (BPS) are counted among the “common diseases” due to the high prevalences. BPH increases with age and is found in about 50% of all men between the 5th and 6th and in 90% between the 8th and 9th decade of life (Berry et al., J Urol 132:474–479, 1984). Similarly, BPS is chronically progressive. BPS describes prostate-related bladder dysfunction caused by a benign prostatic obstruction (BPO). Characteristic are the insidious onset and the variation of the individual disease components such as symptoms “lower urinary tract symptoms”, benign prostatic enlargement (BPE), BPO and their relationship between each other.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berges R (2003) Impact of therapy used in clinical practice on lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) disease progression. Eur Urol Suppl 2:19–24
Berges R (2004) The impact of treatment on lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) progression. Eur Urol Suppl 3:12–17
Berges R (2008) Epidemiologie des benignen Prostatasyndroms. Assoziierte Risiken und Versorgungsdaten bei deutschen Männern über 50. Urologe A 47:141–148
Berges R, Oelke M (2011) Age-stratified normal values for prostate volume, PSA, maximum urinary flowrate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50years or older. World J Urol 29:171–178
Berges R, Pientka L, Höfner K et al (2000) Herne LUTS study: health care seeking behaviour among men aged 50 to 80 with Lower Urinary Tract Symptoms (LUTS) in Germany. J Urol 163:251
Berges RR, Pientka L, Hofner K et al (2001a) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 39:682–687
Berges R, Kühne K, Cubick G et al (2001b) Prevalence of lower urinary tract symptoms (LUTS) related to benign prostatic enlargement (BPE) and their impact on health care seeking. J Urol 165:266
Berges R, Kühne K, Cubick G et al (2002a) Prävalenz von prostatabedingten Miktionsbeschwerden bei Deutschen Männern im Alter über 50 Lebensjahren. Die Herner LUTS-Studie. Urologe A Suppl 1:47A
Berges R, Spiegel T, Senge T (2002b) Gesundheitsbezogene Lebensqualität nach radikaler Prostatektomie und Behandlungszufriedenheit in der Langzeitnachsorge. Urologe B 42:106–108
Berry SJ, Coffey DS, Walsh PC et al (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479
Bruskewitz R, Girman CJ, Fowler J et al (1999) Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS study group. Proscar long-term efficacy and safety study. Urology 54:670–678
Chung WS, Nehra A, Jacobson DJ et al (2004) Lower urinary tract symptoms and sexual dysfunction in community-dwelling men. Mayo Clin Proc 79:745–749
Crawford ED, Wilson SS, Mcconnell JD et al (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175:1422–1426 (discussion 1426–1427)
Donovan JL, Abrams P, Peters TJ et al (1996) The ICS-‘BPH’ Study: the psychometric validity and re-liability of the ICSmale questionnaire. Br J Urol 77:554–562
Donovan JL, Brookes ST, De La Rosette JJ et al (1999) The responsiveness of the ICSmale questionnaire to outcome: evidence from the ICS-‘BPH’ study. BJU Int 83:243–248
Emberton M (2006) Definition of at-risk patients: dynamic variables. BJU Int (Suppl 2) 97:12–15 (discussion 21–22)
Fitzpatrick JM (2006) The natural history of benign prostatic hyperplasia. BJU Int (Suppl 2) 97:3–6 (discussion 21–22)
Hutchison A, Farmer R, Chapple C et al (2006) Characteristics of patients presenting LUTS/BPH in six European countries. Eur Urol 50:555–562
Issa MM, Fenter TC, Black L et al (2006) An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 12:S83–S89
Jacobsen SJ, Guess HA, Panser L et al (1993) A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted county study of urinary symptoms and health status among men. Arch Fam Med 2:729–735
Jacobsen SJ, Jacobsen DJ, Girman CJ et al (2003) Acute urinary retention in community-dwelling men: 9-year follow-up of the Olmsted county study of urinary symptoms and health status among men. J Urol Suppl 169:365 (Abstr. 1364)
Jimenez-Cruz F (2003) Identifying patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) at risk for progression. Eur Urol Suppl 2:6–12
Kok E, Groeneveld F, Gouweloos J et al (2006) Determinants of seeking of primary care for lower urinary tract symptoms: the Krimpen study in community-dwelling men. Eur Urol 50:811–817
Lee SWH, Chan EMC, Lai Y (2017) The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep 7:7984. https://doi.org/10.1038/s41598-017-06628-8
Lieber MM, Jacobsen DJ, Girman CJ et al (2003) Incidence of lower urinary tract symptom progression in community-dwelling men: 9-year follow-up of the Olmsted county study of urinary symptoms and health status among men. J Urol Suppl 169:366 (Abstr. 1369)
Logie J, Clifford GM, Farmer RD (2005) Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int 95:557–562
Lowe FC, Batista J, Berges R et al (2005) Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer Prostatic Dis 8:206–209
Mcconnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical pro-gression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398
Roehrborn CG, Mcconnell JD, Lieber MM et al (1999) Serum prostate-specific antigen concent-ration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group Urol 53:473–480
Sarma AV, Wei JT, Jacobson DJ et al (2003) Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted county study of urinary symptoms and health status and the flint men’s health study. Urology 61:1086–1091
Speakman M, Batista J, Berges R et al (2005) Inte-grating risk profiles for disease progression in the treatment choice for patients with lower urina-ry tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise. Prostate Cancer Prostatic Dis 8:369–374
Van Exel NJ, Koopmanschap MA, McDonnell J et al (2006) Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study. Eur Urol 49:92–102
Verhamme KM, Dieleman JP, Bleumink GS et al (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care–the triumph project. Eur Urol 42:323–328
Verhamme KM, Dieleman JP, Van Wijk MA et al (2005) Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 47:494–498
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer-Verlag GmbH, DE, part of Springer Nature
About this chapter
Cite this chapter
Gross, A.J., Netsch, C. (2023). Epidemiology. In: Netsch, C., Gross, A.J. (eds) Benign Prostate Syndrome. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67057-6_1
Download citation
DOI: https://doi.org/10.1007/978-3-662-67057-6_1
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-67056-9
Online ISBN: 978-3-662-67057-6
eBook Packages: MedicineMedicine (R0)